These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34009661)

  • 1. Application of physiologically based pharmacokinetic models to promote the development of veterinary drugs with high efficacy and safety.
    Zhou K; Mi K; Ma W; Xu X; Huo M; Algharib SA; Pan Y; Xie S; Huang L
    J Vet Pharmacol Ther; 2021 Sep; 44(5):663-678. PubMed ID: 34009661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of Food Animal Residue Avoidance Databank (FARAD) empirical methods for drug withdrawal interval determination with a mechanistic population-based interactive physiologically based pharmacokinetic (iPBPK) modeling platform: example for flunixin meglumine administration.
    Li M; Cheng YH; Chittenden JT; Baynes RE; Tell LA; Davis JL; Vickroy TW; Riviere JE; Lin Z
    Arch Toxicol; 2019 Jul; 93(7):1865-1880. PubMed ID: 31025081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment.
    Lin Z; Gehring R; Mochel JP; Lavé T; Riviere JE
    J Vet Pharmacol Ther; 2016 Oct; 39(5):421-38. PubMed ID: 27086878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges.
    Fairman K; Li M; Ning B; Lumen A
    Biochem Pharmacol; 2021 Jul; 189():114468. PubMed ID: 33577889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
    Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
    Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic modeling of nanoparticles.
    Li M; Al-Jamal KT; Kostarelos K; Reineke J
    ACS Nano; 2010 Nov; 4(11):6303-17. PubMed ID: 20945925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.
    Li M; Zou P; Tyner K; Lee S
    AAPS J; 2017 Jan; 19(1):26-42. PubMed ID: 27834047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic/pharmacodynamic modeling to evaluate the absorption of midazolam rectal gel.
    Zhu J; Zhao Y; Wang L; Zhou C; Zhou S; Chen T; Chen J; Zhang Z; Zhu Y; Ding S; Shao F
    Eur J Pharm Sci; 2021 Dec; 167():106006. PubMed ID: 34520836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
    Ellison CA
    Regul Toxicol Pharmacol; 2018 Nov; 99():61-77. PubMed ID: 30201539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models.
    Lin L; Wong H
    Pharmaceutics; 2017 Sep; 9(4):. PubMed ID: 28954416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults - an AGePOP review.
    Demeester C; Robins D; Edwina AE; Tournoy J; Augustijns P; Ince I; Lehmann A; Vertzoni M; Schlender JF
    Eur J Pharm Sci; 2023 Sep; 188():106496. PubMed ID: 37329924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
    Saeheng T; Na-Bangchang K; Karbwang J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1365-1376. PubMed ID: 29978293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation.
    Franchetti Y; Nolin TD
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S36-S51. PubMed ID: 33205428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
    Moj D; Britz H; Burhenne J; Stewart CF; Egerer G; Haefeli WE; Lehr T
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):1013-1026. PubMed ID: 28988277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
    Boger E; Fridén M
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
    Taskar KS; Pilla Reddy V; Burt H; Posada MM; Varma M; Zheng M; Ullah M; Emami Riedmaier A; Umehara KI; Snoeys J; Nakakariya M; Chu X; Beneton M; Chen Y; Huth F; Narayanan R; Mukherjee D; Dixit V; Sugiyama Y; Neuhoff S
    Clin Pharmacol Ther; 2020 May; 107(5):1082-1115. PubMed ID: 31628859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.